The latest price target for Sutro Biopharma (NASDAQ:STRO) was reported by Wells Fargo on December 11, 2024. The analyst firm set a price target for $4.00 expecting STRO to rise to within 12 months (a possible 103.05% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for Sutro Biopharma (NASDAQ:STRO) was provided by Wells Fargo, and Sutro Biopharma maintained their equal-weight rating.

There is no last upgrade for Sutro Biopharma

There is no last downgrade for Sutro Biopharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sutro Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sutro Biopharma was filed on December 11, 2024 so you should expect the next rating to be made available sometime around December 11, 2025.

While ratings are subjective and will change, the latest Sutro Biopharma (STRO) rating was a maintained with a price target of $5.00 to $4.00. The current price Sutro Biopharma (STRO) is trading at is $1.97, which is out of the analyst’s predicted range.